|Chemical and physical data|
|Molar mass||377.825 g/mol|
|3D model (JSmol)|
Dasolampanel (INN, USAN, code name NGX-426) is an orally bioavailable analog of tezampanel and thereby competitive antagonist of the AMPA and kainate receptors which was under development by Raptor Pharmaceuticals/Torrey Pines Therapeutics for the treatment of chronic pain conditions including neuropathic pain and migraine. It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection, but ultimately neither drug was ever marketed.
- Ian P. Stolerman (31 July 2010). Encyclopedia of Psychopharmacology. Springer Science & Business Media. pp. 514–. ISBN 978-3-540-68698-9.
- Jes Olesen; Nabih Ramadan (21 August 2008). Innovative Drug Development for Headache Disorders. Oxford University Press. pp. 188–. ISBN 978-0-19-955276-4.
- Gary S. Firestein; Ralph Budd; Sherine E Gabriel; James R O'Dell; Iain B. McInnes (31 August 2012). Kelley's Textbook of Rheumatology: Expert Consult Premium Edition: Enhanced Online Features. Elsevier Health Sciences. pp. 1031–. ISBN 1-4557-3767-4.